The short version of cyclic heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
In September 2017, the company announced it would acquire Rigontec, developer of a candidate to target the retinoic acid-inducible gene I pathway, for $554 million. In October 2017, the company granted the inaugural Merck-AGITG Clinical Research Fellowship in Gastro-Intestinal (GI) Cancer to David Lau, a professional in Melbourne, Australia. In June 2018, Merck acquired Viralytics, an Australian viral cancer drug company, for AUD$502 million. In 2018, Merck began the submission process for a Biologics License Application to the Food and Drug Administration under the Breakthrough Therapy Designation for an investigational vaccine, called V920, to fight the Zaire strain of the Ebola virus. In April 2019, the company acquired Immune Design for approximately $300 million, gaining access to its immunotherapy programs. It also acquired Antelliq Group for $2.4 billion, or $3.7 billion including debt. In May 2019, Merck announced it would acquire Peloton Therapeutics, developer of a HIF-2alpha inhibitor for Von Hippel–Lindau disease-associated renal cell carcinoma, for up to $2.2 billion. In June 2019, Merck announced it would acquire Tilos Therapeutics for up to $773 million. In November 2019, the company acquired Calporta, which focused on Parkinsons and Alzheimers treatments. In December 2019, Merck Animal Health acquired Vaki, an aquaculture company, from Pentair.
== Product == The extract is available commercially as Calocurb, an oral dietary supplement for appetite management which was launched in New Zealand in 2018. The capsule has an enteric coating to pass through the stomach and allow delivery to the small intestine.
Hari Singh (1910–2003) was an Indian forestry administrator who served as the Inspector General of Forests of India from 1964 to 1969. He played a foundational role in the country's environmental governance, most notably overseeing the reconstitution of the Indian Forest Service (IFS) into an All India Service in 1966. His tenure emphasized professionalized, scientific forest management, balancing post-independence industrial demands with sustainable ecological practices.
Bonny Light oil was found at Oloibiri in the Niger delta region of Nigeria in 1956 for its commercial use. Due to its features of generating high profit, it is highly demanded by refiners. Bonny light oil has an API of 32.9, classified as light oil. It is regarded as more valuable than the other oils with lower API as more high-value products are produced in the refinement. However, in Nigeria, problems due to oil spillage caused by vandalism affect both humans and the ecosystem in detrimental ways. Some experiments on animals and soil are done to figure out those impacts on organisms.
Sources: en.wikipedia.org
A promising candidate for high-density storage is the face-centered tetragonal phase FePt alloy. Grain sizes can be as small as 3 nanometers. If it's possible to modify the MNPs at this small scale, the information density that can be achieved with this media could easily surpass 1 Terabyte per square inch.
=== Performance-enhancing use === Because they promote lower heart rates and reduce tremors, beta blockers have been used in professional sports where high accuracy is required, including archery, shooting, golf and snooker. Beta blockers are banned in some sports by the International Olympic Committee. In the 2008 Summer Olympics, 50-metre pistol silver medalist and 10-metre air pistol bronze medalist Kim Jong-su tested positive for propranolol and was stripped of his medals. For similar reasons, beta blockers have also been used by surgeons. Classical musicians have commonly used beta blockers since the 1970s to reduce stage fright.
In addition, endogenous progesterone levels naturally increase to extremely high concentrations during pregnancy, yet genital defects do not occur. In accordance, while total concentrations of progesterone in pregnant women at term are around 150 ng/mL (~500 nM), free or unbound and hence bioactive concentrations of progesterone are only about 3 ng/mL (~10 nM) due to the high plasma protein binding of progesterone, and these concentrations are still well below the aforementioned IC50 values for inhibition of 5α-reductase types 1 and 2. As with endogenous progesterone during pregnancy, exogenous supplemental progesterone during pregnancy has been found not to increase the risk of hypospadias in male infants. Although systemic progesterone does not appear to be an effective 5α-reductase inhibitor, topical progesterone may produce potent inhibition of 5α-reductase in the skin due to the very high local concentrations that occur. A study found that topical progesterone applied to the pubic area in men inhibited 5α-reductase in the skin in this region by 75%. In addition to inhibition of 5α-reductase, progesterone is metabolized by 5α-reductase into 5α-dihydroprogesterone (5α-DHP), a compound reported to have some antagonistic activity at the AR. However, this compound appears to have no systemic antiandrogenic activity. In spite of its apparent 5α-reductase inhibition, the effectiveness of topical progesterone in the treatment of pattern hair loss has been poor.
== Further reading == Merck Sharp and Dohme Corporation (22 May 2013). "Suvorexant Advisory Committee Meeting Briefing Document: Peripheral & Central Nervous System Drugs Advisory Committee Meeting" (PDF). Food and Drug Administration. Archived from the original (PDF) on 12 June 2013. Dimova H, Brar S, Men A (2014). "Application Number: 204569Orig1s000. Clinical Pharmacology/Biopharmaceutics Review. Suvorexant (MK-4305)" (PDF). Center for Drug Evaluation and Research (Food and Drug Administration). Archived from the original (PDF) on 5 March 2022.
== Impact == Anderson is credited with the invention of the hamburger bun as well as "the kitchen as assembly line, and the cook as infinitely replaceable technician," hence giving rise to the modern fast-food phenomenon. Due to White Castle's innovation of having chain-wide standardized methods, customers could be sure that they would receive the same product and service in every White Castle restaurant. Ingram's business savvy was responsible not only for White Castle's success but also for the popularization of the hamburger. Time ranked the White Castle slider "The Most Influential Burger of All Time" in its January 14, 2014, edition. The restaurant is a central plot device of the comedy film Harold & Kumar Go to White Castle.
Sources: en.wikipedia.org
The three substrates of this enzyme are taxusin, oxygen, and a proton. It uses a reduced nicotinamide adenine dinucleotide (NADH) cofactor bound to a heme in cytochrome P450 to give 7β-hydroxytaxusin and water as products. The enzyme is found in the yew tree Taxus cuspidata and is part of the pathway for the biosynthesis of taxol.
Data from high-throughput chromosome conformation capture experiments, such as Hi-C (experiment) and ChIA-PET, can provide information on the three-dimensional structure and nuclear organization of chromatin. Bioinformatic challenges in this field include partitioning the genome into domains, such as Topologically Associating Domains (TADs), that are organised together in three-dimensional space. Finding the structure of proteins is an important application of bioinformatics. The Critical Assessment of Protein Structure Prediction (CASP) is an open competition where worldwide research groups submit protein models for evaluating unknown protein models.
NETA is used as a hormonal contraceptive in combination with estrogen, in the treatment of gynecological disorders such as abnormal uterine bleeding, and as a component of menopausal hormone therapy for the treatment of menopausal symptoms. NETA is available in the form of tablets for use by mouth both alone and in combination with estrogens including estradiol, estradiol valerate, and ethinylestradiol. Transdermal patches providing a combination of 50 μg/day estradiol and 0.14 or 0.25 mg/day NETA are available under the brand names CombiPatch and Estalis. NETA was previously available for use by intramuscular injection in the form of ampoules containing 20 mg NETA, 5 mg estradiol benzoate, 8 mg estradiol valerate, and 180 mg testosterone enanthate in oil solution under the brand name Ablacton to suppress lactation in postpartum women. Side effects of NETA include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and others.
7-Fluorotryptamine (7-FT) is a serotonin receptor modulator and weak GPRC5A agonist of the tryptamine family. It is the 7-fluoro derivative of tryptamine. The drug is a low-potency agonist of the orphan receptor GPRC5A, with an EC50Tooltip half-maximal effective concentration of 7,200 nM. In addition to its GPRC5A agonism, 7-fluorotryptamine interacts with other receptors, such as the serotonin 5-HT4 receptor. Derivatives of 7-fluorotryptamine have been described. 7-Fluorotryptamine was first described in the scientific literature by 1979. Its GPRC5A agonism was first described in 2023. Substituted tryptamine 7-Chlorotryptamine 7-Methyltryptamine 7-Hydroxytryptamine 7-F-5-MeO-MET 7-Chloro-AMT 7-Fluorotryptamine - Isomer Design
While the method of chemical characterization of a daughter was successful for flerovium and livermorium, and the simpler structure of even–even nuclei made confirmation of oganesson (Z = 118) straightforward, there have been difficulties in establishing the congruence of decay chains from isotopes with odd protons, odd neutrons, or both. To get around this problem with hot fusion, the decay chains from which terminate in spontaneous fission instead of connecting to known nuclei as cold fusion allows, experiments were done in Dubna in 2015 to produce lighter isotopes of flerovium by reaction of 48Ca with 239Pu and 240Pu, particularly 283Fl, 284Fl, and 285Fl; the last had previously been characterized in the 242Pu(48Ca,5n)285Fl reaction at Lawrence Berkeley National Laboratory in 2010. 285Fl was more clearly characterized, while the new isotope 284Fl was found to undergo immediate spontaneous fission, and 283Fl was not observed. This lightest isotope may yet conceivably be produced in the cold fusion reaction 208Pb(76Ge,n)283Fl, which the team at RIKEN in Japan at one point considered investigating: this reaction is expected to have a higher cross-section of 200 fb than the "world record" low of 30 fb for 209Bi(70Zn,n)278Nh, the reaction which RIKEN used for the official discovery of element 113 (nihonium). Alternatively, it might be produced in future as a great-granddaughter of 295120, reachable in the 249Cf(50Ti,4n) reaction.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.